Acute myeloid leukemia
Conditions
Interventions
case series:Decitabine: 10 mg Subcutaneous injection one time/day, consecutively 5 days in a month x 8 -12 times
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years, male or female; 2. Patients after transplantation for 1 months have decitabine as routine maintenance therapy for 1 year; 3. Patients never accepted maintenance therapy, companied with persistent positive minimal residual lesions (MRD); 4. Routine blood indexes should be normal in each case; 5. Ability to understand and be willing to sign the informed consent form of this trial.
Exclusion criteria
Exclusion criteria: 1. pregnant women or lactation women; 2. patients with uncontrolled heart failure, unstable angina, arrhythmia or mental disorders; 3. uncontrolled infection disease; complicated with serious heart, lung, liver or kidney disease; 4. HIV infected patients; 5. Patients with 3 or high stage chronic renal disease. 6. Relapsed completely in the peripheral blood and bone marrow.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission of hematology on morphology;Minimal residue diseases;event-free survival;overall survival;cumulative disease rate of relapse ;Relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| early mortality rate ; | — |
Countries
China
Contacts
Public ContactWang Li
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed